Latest data on GLP-1 drugs is that a large proportion of users are giving up taking them due to side effects. After all they were not designed for weight loss but to treat a serious disease and I suspect people with this disease will accept some side effects more than a healthy but over weight person. Therefore short term, GLP-1 drugs may start to lose their attractiveness but my core opinion remains unchanged - longer-term there are better weight loss drugs on the way and this will impact RMD. Remember RMD is a very specialized business. A strength and a weakness.
Latest data on GLP-1 drugs is that a large proportion of users...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$32.96 |
Change
0.210(0.64%) |
Mkt cap ! $20.46B | |||
| Open | High | Low | Value | Volume |
| $32.86 | $33.12 | $32.85 | $92.47M | 2.801M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 717 | $32.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $32.98 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$33.00 |
Change
0.210 ( 0.59 %) |
||||
| Open | High | Low | Volume | ||
| $32.89 | $33.11 | $32.86 | 421229 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| RMD (ASX) Chart |